SCHEMBL20356709

SCHEMBL20356709

Cc1nc(C(=O)O)nc(OCc2cccc(F)c2)c1Cc1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.42
▸ KDM4E B2RXH2 3/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ MRGPRX4 Q96LA9 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAOB P27338 4/20 0.39
▸ HPGD P15428 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MITF O75030 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20356576 0.90 SMN1; SMN2 (0.44) NR4A2TDP1SMN1; SMN2ALDH1A1LMNA
SCHEMBL20356707 0.89 SMN1; SMN2 (0.41) NR4A2KDM4ETDP1SMN1; SMN2MEN1
SCHEMBL21526008 0.86 PTGER1 (0.43) SMN1; SMN2ALDH1A1LMNAHTTMAPT
SCHEMBL21526056 0.86 PDCD1 (0.43) MRGPRX4MAOBSLC16A3SLC16A1MCTS1
SCHEMBL20356708 0.85 ALDH1A1 (0.43) NR4A2KDM4ETDP1SMN1; SMN2ALDH1A1
SCHEMBL20356567 0.84 SMN1; SMN2 (0.41) NR4A2TDP1SMN1; SMN2MEN1KMT2A
SCHEMBL21526079 0.83 GPR132 (0.44) TDP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL21526094 0.82 SMN1; SMN2 (0.40) NR4A2KDM4ETDP1SMN1; SMN2MEN1
SCHEMBL21525997 0.81 SMN1; SMN2 (0.46) NR4A2TDP1SMN1; SMN2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL21526118 0.80 SMN1; SMN2 (0.45) NR4A2TDP1SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-11034659-B2 Pyrimidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-15 — — US disclosed
US-20200172494-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-06-04 — — US disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
WO-2018124000-A1 PYRIMIDINE DERIVATIVE 第一三共株式会社 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034659-B2 Pyrimidine derivative GPR39, CFTR, TMEM109 NR4A2 780/4885KDM4E 4694/4885TDP1 4760/4885
US-20200172494-A1 PYRIMIDINE DERIVATIVE GPR39, CFTR, TMEM109 NR4A2 780/4885KDM4E 4694/4885TDP1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback